期刊文献+

阿立哌唑片在中国健康志愿者体内的药动学

Pharmacokinetics study of aripiprazole tablets in Chinese healthy volunteers
下载PDF
导出
摘要 目的:研究阿立哌唑片在中国健康志愿者体内的药动学。方法:单剂量试验组:10名健康志愿者(男女各半),分3阶段先后单剂量口服阿立哌唑10,20,40mg。多剂量试验组:12名健康志愿者(男女各半),连续口服阿立哌唑20mg(qd,连续14d)。血药浓度采用HPLC法测定,以计算其主要药动学参数并进行统计学分析。结果:单剂量口服阿立哌唑10,20,40mg后,主要药动学参数分别如下:AUC0。为(16431.8±2350.5)、(40184.0±5256.7)和(71629.1±8616.5)μg·h·L^-1;tmax为(4.4±1.3)、(4.2±0.8)和(4.3±0.9)h;Cmax为(187.2±20.9)、(410.1±58.3)和(700.8±143.6)μg·L^-1;t1/2β为(83.22±9.43)、(75.11±10.06)和(84.17±22.43)h。方差分析结果显示各剂量的主要药动学参数AUC0-1,tmax,Cmax,和t1/2β均没有性别间差异。多利量口服阿立哌唑片20mg达到稳态后的主要药动学参数如下:AUCss^τ为(11961.1±2675.7)μg·L^-1;fmax^ss为(4.4±1.2)h;Cmax^ss为(634.2±137.1)μg·L^-1;Cmin^ss为(361.3±95.7)μg·L^-1;Cav为(498.4±111.5)μg·L^-1;DF为(55.6±7.5)%,t1/2β为(66.42±12.65)h。经方差分析,除tmax^ss外,多剂量主要药物动力学参数性别间无显著性差异。结论:健康志愿者单剂量和多剂量口服阿立哌唑片后体内药物浓度呈二室模型变化规律;在10-40mg剂量范围内,血药峰浓度及血药浓度-时间曲线下面积与剂量之间呈线性关系,其主要药动学参数无性别差异。 OBJECTIVE To research the pharmacokinetics of aripiprazole in healthy volunteers after administration with single or multiple dose of aripiprazoLe, and compare its gender difference. METHODS In single dose study, 6 male and 6 female volunteers received a single dose of 10,20,40 mg aripiprazole tablets, respectively in 3 stages. In multiple dose study, other 6 male and 6 female volunteers administered aripiprazole tablets(20 mg, qd, for 14 days). Aripiprazole concentration in plasma was determined by HPLC. Main pharmacokinetic parameters were calculated and compared by statistic analysis. RESULTS The pharmacokinetic parameters obtained from the single-dose study of 10,20,40 mg were, respectively, as follows: AUG0-t (16431.8±2350.5),(40184.0±5256.7)and(71629.1±8616.5)μg·h·L^-1;tmx(4.4±1.3),(4.2±0.8)and(4.3±0.9)h; Cmax ( 187. 2 ± 20. 9), (410. 1 ± 58. 3) and (700. 8 ±143. 6) μg·L^-1 ; t1/2,β (83.22 ± 9. 43), (75. 11 ± 10. 06) and (84. 17 ± 22. 43) h. The steady-state pharrnacokinetic parameters were as follows: AUCss^t (11961.1 ± 2675.7)μg·h·L^-1 ;tmax^ss为(4. 4 ± 1.2)h; Cmax^ss(634.2± 137. 1)μg·L^-1;Cmin^ss(361.3±95.7)μg·L^-1;Cav(498.4±111. 5)μg·L^-1;DF(55.6±7.5) %;t1/2β(66.42± 12.65) h. Statistical analysis indicated that there was no gender difference in pharmacokinetic parameters, except of tmax^ss in multiple dose study. CONCLUSION The concentration-time curves of aripiprazole are fitted to a two-compartment model. In the dose range of 10-40 mg, Cmax and AUC0-t: follow the rule of dose-dependant manner. There was no gender difference in the main pharmacokinetic parameters.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第5期351-354,共4页 Chinese Journal of Hospital Pharmacy
关键词 阿立哌唑 高效液相色谱 药动学 aripiprazole HPLC pharmacokinetic
  • 相关文献

参考文献6

  • 1张鸿燕,马弘.阿立哌唑[J].中国新药杂志,2003,12(10):868-869. 被引量:103
  • 2罗荣.阿立哌唑——新型抗精神病药[J].现代诊断与治疗,2003,14(6):372-373. 被引量:24
  • 3左笑丛,李焕德.新抗精神病药物阿立哌唑的药代动力学[J].中国临床药理学杂志,2005,21(6):470-474. 被引量:10
  • 4Mallikaarjun S, Salazar D E, Bramer S L. Pharrnaeokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in Normal Healthy Volunteers[J]. J Clin Pharmaeol, 2(1(14,441179 187. 被引量:1
  • 5Xiao-Cong Zuo, Shi-Kun Liu, Hua-nDe Li,et al. Steady-State Pharmaeokinetic Properties of Aripiprazole 10 mg PO q12h in Han Chinese Adults with Schizophrenia: A Prospective, Open- Label, Pilot Study[J]. Current Therapeutic Research, 2006, 67(4) : 258-269. 被引量:1
  • 6国家食品药品监督管理局.化学药品制剂人体生物利用度和生物等效性研究技术指导原则(第二稿)[s].2005:1. 被引量:1

二级参考文献41

  • 1.FDA网上公告[EB/OL].Http://www.fda.gov,. 被引量:1
  • 2Jordan S, Kopriviea V, Chen R, et al, The antipsyehotic aripiprazole is a potent, partial agonist at the human 5-HT1A reeeptor[J].Eur J Pharmacol, 2002, (441 ) : 137 - 140. 被引量:1
  • 3Hirose T, Uwahodo Y, Yamada S, et al. Efficacy and favorable side-effect profile of aripiprazole determined in rat with apomorphine-induced stereotype, catalepsy, and ptosis induction [ J ]. Int J Neuropsychopharm, 2000,3 (Suppl) :S131 - S136. 被引量:1
  • 4Burris KD, Molski TF, Ryan E, et al. Aripiprazole is a high affinity partial agonist at human D2 doparnine receptors[J]. Int J Neuropsychopharm ,2000,3(Suppl) :S129 - S130. 被引量:1
  • 5Jordan S, Kopriviea V, Chen R, et al. The antipsyehotie aripiprazole is a potent partial agonist at the human 5-HTIA receptors[J]. Eur Neuropsychopharm, 2001,11 (Suppl 3) :S268 - S273. 被引量:1
  • 6Petrie J L, Saha AR, McEvoy JP, Aripiprasole, a new antipsychotic: phase Ⅱ clinical trial result [J ]. Eur Neuropsychopharm,1997,7(Suppl 2) :S227 - S230. 被引量:1
  • 7Daniel DG,Saha AR, Ingenito G, et al. Aripiprazole,a novel antipsyehotie:overview of a phase Ⅱ study result[J]. Int J Neuropsychopharm, 2000,3 (Suppl 1 ) : S157 - S160. 被引量:1
  • 8Kane J, Ingenito G, All M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo [J ]. Int J Neuropsychopharm, 2000,3 (Suppl 1 ) : S124 - S128. 被引量:1
  • 9Carson WH, Kane J, Ali M, et al. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo[J]. Int J Neuropsychopharm, 2000,10 (Suppl 3) : S309 - S312. 被引量:1
  • 10Saha AR,Carson WH,Ali MW,et al. Efficacy and safety of aripiprazole and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder[J]. WJ Biol Psychiat ,2001,2(Suppl1) : S305 - S308. 被引量:1

共引文献130

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部